Salestools LogoSalestools
Agentes IA de Salestools
Soluciones
Recursos
Empresa
Precios
Salestools Logo

Salestools

El agente IA #1 para equipos de ventas y Go-to-Market. Vende más, más rápido, con menos esfuerzo.

Producto

  • Agentes de ventas IA
  • Datos de intención
  • Datos tecnológicos
  • Seguimiento de visitantes
  • Co-Pilot
  • Venta social

Soluciones

  • Servicio al cliente
  • Comercio electrónico
  • SaaS
  • Empresarial
  • Pequeña empresa

Recursos

  • El informe
  • Documentación
  • Referencia de API
  • Centro de ayuda
  • Blog
  • Casos de estudio
  • Webinars

Empresa

  • Acerca de
  • Carreras
  • Prensa
  • Contacto
  • Socios

Nuestras ubicaciones

  • Nueva York, HQ
  • Bucarest, laboratorio de investigación IA
  • Zug, Suiza

© 2025 Salestools. Todos los derechos reservados.

Términos de datos y seguridadPolítica de privacidadTérminos de servicio
Todos los sistemas operativos
Salestools LogoSalestools
Agentes IA de Salestools
Soluciones
Recursos
Empresa
Precios
Back to The Report
Biotech

Vima Therapeutics

Vima Therapeutics raises $60M Series A at $280M valuation

$60M
Total Raised
Series A
Latest Round
2023
Founded
50+
Employees
Cambridge, MA
Updated May 24, 2024
1 min read

Quick Facts

Valuation
$280M
Latest Round Size
$60M
Latest Round Date
May 2024

Vima Therapeutics: Series A Funding Round

Vima Therapeutics has successfully raised $60M in Series A funding, reaching a valuation of $280M.

Company Overview

Focused on oral therapies for movement disorders

Funding Details

The Series A round was led by Third Rock Ventures, with participation from Arch Venture Partners.

Company Information

  • Headquarters: Cambridge, MA
  • Founded: 2023
  • Employees: 50+
  • Category: Biotech

Investment

Vima Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Third Rock Ventures: Verified investor in Series A
  • Arch Venture Partners: Verified investor in Series A

Key Investors

Third Rock Ventures
Lead Investor
Verified investor in Series A
Arch Venture Partners
Investor
Verified investor in Series A

Topics

verified(3079)real-funding(3079)vima-therapeuticsbiotechseries-acambridge

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M